Pediatrics Doctors in Troy, AL Accepting Medicare

5 Pediatrics doctors found. Showing 1 - 5

Yolanda A Patterson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1300 Highway 231 S, Troy, AL 36081 Phone: 334-566-7600    Fax: 334-566-1445

Dr. Elizabeth N Dawson, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1300 United States Highway 231 South, Troy, AL 36081 Phone: 334-566-7600

Melody Floyd Byram, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 657 Trojan Pkwy, Troy, AL 36079 Phone: 334-934-5437

Patricia A Block, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1300 Highway 231 S, Troy, AL 36081 Phone: 334-566-7600    Fax: 334-566-1445

Jerry C Roy, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1412 Elba Hwy, Troy, AL 36079 Phone: 334-566-8822    Fax: 334-808-8942

News Archive

Omega-3 fatty acids did not reduce risk of cardiac events in elderly heart attack survivors

A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary heart attack, stroke, bypass surgery or death, among elderly people who had survived a recent heart attack, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.

Tick's salivary glands could become key research tools for studying virus transmission

The salivary glands of some tick species could become important research tools for studying how viruses are transmitted from ticks to mammals, and for developing preventive medical countermeasures.

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.

NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801

Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).

Islet Sciences acquires DTI

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the closing of the acquisition of DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes which is now the Company's wholly owned subsidiary.

Read more Medical News

› Verified 4 days ago